Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Turn Sakaguchi’s Nobel-Winning Research into Societal Impact: LDP Panel Chief
October 8, 2025
- Takaichi Vows Hospital Support via Extra Budget; MHLW Sees Boost for Funding Requests
October 7, 2025
- Japan to Allow Vaccine Strain Changes Under PACMP Framework
October 6, 2025
- Japan Health Minister Mum on NIP Use of RSV Preventives for Children
October 6, 2025
- Panel Split on Delisting OTC-Like Drugs from Insurance Coverage
October 3, 2025
- SanBio’s Akuugo Set for Re-Review on Oct. 16, Shipment Decision Nears
October 3, 2025
- Japan Will Receive MFN Status on US Drug Tariffs: Akazawa
October 1, 2025
- MHLW Council Clears Public Knowledge Filing for MabCampath in T-PLL
October 1, 2025
- Takeda’s Oveporexton Gets Sakigake Tag for Narcolepsy Type 1
September 30, 2025
- Japan Hands Out Orphan Tags to 10 Compounds
September 30, 2025
- Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
- Panel Flags Concern over Drug-Only Focus in Proposed Cost-Cuts for 2026 Reform
September 29, 2025
- US Confirms 50% Tariffs on Japan’s Heavy Trucks; Pharma Capped at 15%
September 29, 2025
- Japan to Set Criteria for “Challenge Applications” in Medical Device Pricing Reform
September 29, 2025
- Japan Says It’s Too Early to Gauge Impact of US Pharma Tariffs
September 29, 2025
- Pharma Support Needed to Bridge Biotech’s “Valley of Death”: Council Member
September 26, 2025
- Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
- LDP Leadership Race Underway, Healthcare-Savvy Lawmakers Among Endorsers
September 24, 2025
- FPMAJ Calls for Scrapping Huge-Seller, Spillover Re-Pricing at Public-Private WG Hearing
September 24, 2025
- Japan OKs Biosimilars of Eylea, Actemra, Simponi, Ranmark in Likely First Debut
September 22, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…